The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...
The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...
Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.
The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss medications received by RFK Jr.
U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...
Novo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that ...
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
President Joe Biden plans to require Medicare and Medicaid to offer coverage for weight-loss medications, a move that could ...
Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...
The good news is that HHS recognizes that vitally important anti-obesity medicines like Wegovy and Zepbound should be made available to all Americans, regardless of income. The bad news is that unless ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback